DULUTH, Ga., May 8 /PRNewswire/ -- Metametrix Clinical Laboratory ( http://www.metametrix.com ), a leader in nutritional and metabolic testing, announced the introduction of the urinary Neopterin/Biopterin Profile. This latest testing profile measures the oxidative products of tetrahydrobiopterin (BH4).
Neopterin and biopterin are by-products of the redox reactions involving tetrahydrobiopterin (BH4). Restricted BH4 availability has been suggested as an etiologic factor in neurological diseases such as Alzheimer's disease, Parkinson's disease, Autism Spectrum Disorders, depression, and DOPA-responsive dystonia; insulin resistance; cardiovascular disease, and inborn-errors of metabolism including phenylketonuria and hyperphenylalaninemia. Neopterin is also found elevated in infections; autoimmune diseases, such as rheumatoid arthritis, systemic lupus, and atopic asthma; malignant disease; psychiatric disorders; and sleep-disordered breathing. Low biopterin levels may reflect insufficient BH4 status.
From a simple overnight urine collection, the test measures neopterin, biopterin, a ratio of the two, as well as creatinine to allow detection and monitoring of BH4. Supplementation and treatment plans can then be implemented to improve BH4 enzyme deficiencies. Neopterin/Biopterin is the latest in a series of available "Health Risk Profiles" from Metametrix and is available as an add-on to its Organix(SM), Toxic Effects(SM) Porphyrins, ION(SM), Cardio/ION(SM), and TRIAD(SM) profiles. For a complete list of Metametrix laboratory services and related research, visit the website at: http://www.metametrix.com .
Metametrix Clinical Laboratory has for the past 24 years specialized in producing innovative, Next Generation Technologies(SM) for measuring nutritional, metabolic, and toxic influences on health. Metametrix is a leader in providing quality, innovation, and education with integrative and functional testing services to healthcare professionals around the world.
For Information: http://www.metametrix.com
|SOURCE Metametrix Clinical Laboratory|
Copyright©2008 PR Newswire.
All rights reserved